• 1. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Taxanes and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Diterpenoids Taxanes and derivatives
• Diterpenoids
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances
• Other Chemical Reagents

Recent Advances in the Study of 9-Dihydro-13-acetylbaccatin III (CAS: 142203-65-4): A Comprehensive Research Brief

9-Dihydro-13-acetylbaccatin III (CAS: 142203-65-4) is a semi-synthetic derivative of baccatin III, a key intermediate in the production of taxane-based chemotherapeutic agents such as paclitaxel and docetaxel. This compound has garnered significant attention in recent years due to its potential applications in cancer therapy and its role in the biosynthesis of taxane derivatives. The present research brief aims to synthesize the latest findings on this compound, focusing on its chemical properties, biological activities, and therapeutic potential.

Recent studies have highlighted the structural modifications of 9-Dihydro-13-acetylbaccatin III to enhance its bioavailability and efficacy. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that specific functional group substitutions at the C-13 position could significantly improve the compound's solubility and tumor-targeting capabilities. These modifications are critical for overcoming the limitations associated with traditional taxane therapies, such as drug resistance and systemic toxicity.

In addition to its role as a precursor for taxane synthesis, 9-Dihydro-13-acetylbaccatin III has shown promising standalone anticancer properties. A preclinical study conducted by researchers at the National Cancer Institute revealed that the compound exhibits potent antiproliferative effects against a range of cancer cell lines, including breast, ovarian, and lung cancers. Mechanistic studies indicated that these effects are mediated through the stabilization of microtubules, similar to paclitaxel, but with a distinct binding affinity that may reduce off-target effects.

The synthesis and scalable production of 9-Dihydro-13-acetylbaccatin III have also seen advancements. A 2024 report in Organic Process Research & Development detailed a novel enzymatic method for the large-scale production of this compound, offering a more sustainable and cost-effective alternative to traditional chemical synthesis. This innovation is expected to facilitate further research and clinical development of 9-Dihydro-13-acetylbaccatin III and its derivatives.

Despite these advancements, challenges remain in the clinical translation of 9-Dihydro-13-acetylbaccatin III. Pharmacokinetic studies have identified issues related to rapid metabolism and clearance, necessitating the development of advanced drug delivery systems. Recent efforts in nanotechnology, such as liposomal encapsulation and polymer-based carriers, have shown promise in addressing these challenges, as evidenced by a 2023 study in Biomaterials Science.

In conclusion, 9-Dihydro-13-acetylbaccatin III (CAS: 142203-65-4) represents a versatile and promising candidate in the field of oncology and drug development. Ongoing research continues to uncover its potential, with a focus on optimizing its chemical structure, enhancing its therapeutic efficacy, and overcoming pharmacokinetic barriers. The integration of innovative synthesis methods and advanced delivery technologies is expected to propel this compound into clinical trials in the near future.

• 873001-54-8(3,29-Dibenzoyl Rarounitriol)
• 705973-69-9(14beta-Benzoyloxy-2-deacetylbaccatin VI)
• 134-09-8(Menthyl anthranilate)
• 604-32-0(Cholesterol Benzoate)
• 210108-90-0((2R,3R,3aS,4R,6S,7S,8S,12S,13S,13aR,E)-3-(benzoyloxy)-7,13a-dihydroxy-2,9,9,12-tetramethyl-5-methylene-2,3,3a,4,5,6,7,8,9,12,13,13a-dodecahydro-1H-cyclopenta[12]annulene-2,4,6,8,13-pentayl pentaacetate)
• 84-61-7(Dicyclohexyl phthalate)
• 210108-86-4(Jatrophane 2)
• 220935-39-7(1H-Azuleno[5',6':3,4]benz[1,2-b]oxete-4,5,6,8,10,10b(2aH)-hexol,4a-[(acetyloxy)methyl]-3,4,5,6,8,9,10,10a-octahydro-9a-(1-hydroxy-1-methylethyl)-7-methyl-,10b-acetate 10-benzoate, (2aR,4S,4aR,5R,6R,8S,9aS,10S,10aR,10bS)-)
• 153229-31-3(1H-Azuleno[5',6':3,4]benz[1,2-b]oxete-4,5,6,8,10,10b(2aH)-hexol,3,4,4a,5,6,8,9,9a,10,10a-decahydro-9a-(1-hydroxy-1-methylethyl)-4a,7-dimethyl-,4,5,10,10b-tetraacetate 6-benzoate, (2aR,4S,4aS,5R,6R,8S,9aS,10S,10aR,10bS)-)
• 57672-79-4(Baccatin VI)